Angela Schulz Selected Research

Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis)

10/2022	Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 Disease and ICV-Enzyme Replacement Therapy: A Case Report.
6/2022	Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
5/2022	The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.
1/2021	Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
1/2021	Management of CLN1 Disease: International Clinical Consensus.
1/2021	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
11/2019	Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
5/2019	Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
1/2019	Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.
1/2019	Lysosomal proteome analysis reveals that CLN3-defective cells have multiple enzyme deficiencies associated with changes in intracellular trafficking.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angela Schulz Research Topics

Disease

18	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 10/2022 - 05/2009
13	Albuminuria 01/2020 - 07/2002
8	Hypertension (High Blood Pressure) 03/2014 - 08/2003
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018 - 11/2010
4	Epilepsy (Aura) 01/2021 - 01/2018
4	Obesity 01/2018 - 01/2012
4	Nephrogenic Diabetes Insipidus 04/2012 - 11/2002
4	Fibrosis (Cirrhosis) 04/2011 - 01/2007
3	Disease Progression 11/2022 - 01/2011
3	Infections 01/2021 - 01/2011
3	Cystic Fibrosis (Mucoviscidosis) 10/2020 - 11/2015
3	Body Weight (Weight, Body) 01/2018 - 01/2011
3	Stroke (Strokes) 07/2012 - 07/2004
3	Hypertrophy 08/2011 - 01/2007
2	Glaucoma 01/2022 - 01/2020
2	Seizures (Absence Seizure) 01/2021 - 01/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 01/2016
2	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2021 - 12/2017
2	Hypersensitivity (Allergy) 01/2021 - 01/2011
2	Overweight 11/2020 - 01/2018
2	Chronic Renal Insufficiency 01/2020 - 01/2018
2	Dementia (Dementias) 05/2019 - 01/2018
2	Neoplasms (Cancer) 07/2017 - 01/2017
2	Hypercholesterolemia 01/2016 - 02/2009
2	Cardiomyopathies (Cardiomyopathy) 01/2016 - 01/2012
2	Proteinuria 01/2010 - 01/2007
1	COVID-19 10/2022
1	Retinal Degeneration 06/2022
1	Isolated Systolic Hypertension 01/2022
1	Cardiomegaly (Heart Hypertrophy) 01/2022
1	Pain (Aches) 12/2021
1	Fever (Fevers) 01/2021
1	Rare Diseases (Rare Disease) 01/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021
1	Pediatric Obesity 11/2020
1	Ganglion Cysts (Ganglion) 01/2020
1	Neurodevelopmental Disorders 01/2020
1	Allan-Herndon-Dudley syndrome 01/2020
1	Friedreich Ataxia (Friedreich's Ataxia) 06/2019
1	Inborn Genetic Diseases (Disease, Hereditary) 05/2019
1	Neuromyelitis Optica (Devic's Disease) 01/2019
1	Multiple Sclerosis 01/2019
1	Neuroinflammatory Diseases 01/2019
1	Noncommunicable Diseases 01/2018
1	Leukemia 01/2018
1	T-Cell Leukemia (Leukemia, T Cell) 01/2018

Drug/Important Bio-Agent (IBA)

12	EnzymesIBA 01/2021 - 01/2016
8	Tripeptidyl-Peptidase 1IBA 01/2021 - 01/2016
5	Retinaldehyde (Retinal)IBA 11/2022 - 08/2015
5	cerliponase alfaIBA 06/2022 - 01/2018
5	SaltsIBA 07/2012 - 08/2003
4	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 04/2012 - 11/2002
3	CytokinesIBA 01/2018 - 03/2011
3	AutoantibodiesIBA 01/2016 - 01/2012
3	Triglycerides (Triacylglycerol)IBA 01/2016 - 01/2007
3	CholesterolIBA 01/2016 - 01/2007
3	Messenger RNA (mRNA)IBA 04/2011 - 01/2007
2	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2011
2	finerenoneIBA 01/2020 - 01/2018
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 03/2014
2	MelanocortinsIBA 01/2017 - 01/2016
2	LipidsIBA 01/2016 - 02/2009
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2016 - 01/2011
2	Glucose (Dextrose)FDA LinkGeneric 08/2014 - 01/2011
2	NG-Nitroarginine Methyl Ester (L-NAME)IBA 03/2014 - 06/2010
2	Proteins (Proteins, Gene)FDA Link 08/2011 - 05/2009
2	CreatinineIBA 04/2011 - 01/2007
2	salicylhydroxamic acid (SHAM)IBA 06/2010 - 09/2009
2	AlbuminsIBA 11/2007 - 01/2007
1	lipopigmentsIBA 05/2022
1	Desoxycorticosterone Acetate (DOCA)FDA Link 01/2022
1	AntibodiesIBA 01/2021
1	palmitoyl-protein thioesteraseIBA 01/2021
1	ParabensIBA 11/2020
1	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 11/2020
1	neodymium pyrocatechin disulfonate (NPD)IBA 10/2020
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 10/2020
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	Thyroid HormonesIBA 01/2020
1	idebenoneIBA 06/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2019
1	ProteomeIBA 01/2019
1	Lysosomal Membrane ProteinsIBA 01/2019
1	Therapeutic UsesIBA 01/2018
1	bisphenol AIBA 01/2018
1	wogoninIBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	FlavonoidsIBA 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2018

Therapy/Procedure

8	Therapeutics 10/2022 - 01/2016
4	Enzyme Replacement Therapy 10/2022 - 01/2018
1	Enzyme Therapy 10/2022
1	Critical Care (Surgical Intensive Care) 10/2022
1	Terminal Care (Care, Terminal) 01/2021
1	Intraventricular Infusions 01/2021
1	Pain Management 01/2021
1	Transplantation 01/2018